{"classes":[{"categories":[{"measurements":[{"comment":"NA=Not Estimable. Data are not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"4.6","upperLimit":"NA","value":"12.2"},{"groupId":"OG001","lowerLimit":"6.5","upperLimit":"13.6","value":"10.1"},{"groupId":"OG002","lowerLimit":"5.7","upperLimit":"17.6","value":"10.8"},{"comment":"NA=Not Estimable. Data are not estimable due to insufficient number of participants with events.","groupId":"OG003","lowerLimit":"6.6","upperLimit":"NA","value":"11.9"},{"comment":"Data are not estimable due to insufficient number of participants with events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA=Not Estimable. Data are not estimable due to insufficient number of participants with events.","groupId":"OG005","lowerLimit":"1.3","upperLimit":"NA","value":"8.4"},{"comment":"NA=Not Estimable. Data are not estimable due to insufficient number of participants with events.","groupId":"OG006","lowerLimit":"5.3","upperLimit":"NA","value":"7.3"},{"comment":"NA=Not Estimable. Data are not estimable due to insufficient number of participants with events.","groupId":"OG007","lowerLimit":"1.6","upperLimit":"NA","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"description":"Overall Survival (OS) is defined as the time from first dose of study drug until date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"300mg DKN-01 monotherapy in recurrent EEC. DKN-01 administered by IV infusion.","id":"OG000","title":"DKN-01 Monotherapy in Recurrent EEC"},{"description":"300mg DKN-01+paclitaxel in recurrent EEC. DKN-01 and paclitaxel administered by IV infusion.","id":"OG001","title":"DKN-01 + Paclitaxel in Recurrent EEC"},{"description":"300mg DKN-01 monotherapy in recurrent EOC. DKN-01 administered by IV infusion.","id":"OG002","title":"DKN-01 Monotherapy in Recurrent EOC"},{"description":"300mg DKN-01+paclitaxel in recurrent EOC. DKN-01 and paclitaxel administered by IV infusion.","id":"OG003","title":"DKN-01 + Paclitaxel in Recurrent EOC"},{"description":"300mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.","id":"OG004","title":"DKN-01 300mg Monotherapy in Carcinosarcoma"},{"description":"600mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.","id":"OG005","title":"DKN-01 600mg Monotherapy in Carcinosarcoma"},{"description":"300mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.","id":"OG006","title":"DKN-01 300mg + Paclitaxel in Carcinosarcoma"},{"description":"600mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.","id":"OG007","title":"DKN-01 600mg + Paclitaxel in Carcinosarcoma"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS), all subjects who received any amount of DKN-01.","reportingStatus":"POSTED","timeFrame":"Baseline to study completion (maximum 17.6 months)","title":"Overall Survival (OS) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).","type":"SECONDARY","unitOfMeasure":"months"}